Roles
- Assistant Professor of Clinical Medicine
-
Biography
Dr. Spiegel is an Assistant Professor who joined the University of Miami in 2021 with a clinical focus on cellular therapy for hematologic malignancies. He is a translational researcher working to improve CAR-T cell outcomes for B cell malignancies and has led first in human trials of novel CAR-T therapies as well as investigator-initiated trials testing CAR-T in combination with targeted therapies. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Sylvester Comprehensive Cancer Center Researchers Discover Why Some Lymphomas Resist CAR T-cell Treatment
Sylvester Comprehensive Cancer Center at ASH 2025: Advancing Blood Cancer Science Through Collaboration
Stacked Approaches Give New Hope for Patients with Hard-to-Treat Lymphoma
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 7 clinical trials.
-
The purpose of this study is to find out what effects the CB-011 therapy may have on your cancer. For patients with r/r multiple myeloma, CB-011 is designed to address an unmet medical need.
- Principal Investigator: Jay Spiegel
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of the study is to evaluate the safety and efficacy of treatment with pirtobrutinib and standard of care brexucabtagene autoleucel in patients with mantle cell lymphoma (MCL).
- Principal Investigator: Jay Spiegel
- Study Phase: Phase II
- Enrollment Status: Open
-
To compare the incidence rate of serious bacterial infections during the first six months after CD19-CARTx in patients randomized to receive monthly antibody infusions versus placebo in a modified intention-to-treat (mITT) analysis.
- Principal Investigator: Jay Spiegel
- Study Phase: Phase II
- Enrollment Status: Open
-
The primary purpose of this study is to determine the safety, tolerability, and efficacy of CRG-022. Some doctors have noticed an improvement in cancer in subjects taking other genetically modified cells during other research studies.
- Principal Investigator: Jay Spiegel
- Study Phase: Phase II
- Enrollment Status: Closed
-
The purpose of this study is to find out if the experimental product, KITE-197, is safe and effective in treating your relapsed or refractory large B-cell lymphoma. This is the first time KITE-197 is being used in humans.
- Principal Investigator: Jay Spiegel
- Study Phase: Phase I
- Enrollment Status: Closed
-
ADI-001 is an investigational new cell-based drug product that is made from T cells, a type of white blood cell, that are taken from healthy donors. These T cells have been gene-modified to express a surface protein that permits the recognition and destruction of your lymphoma cancer cells.
- Principal Investigator: Jay Spiegel
- Study Phase: Phase I
- Enrollment Status: Closed
-
The purpose of this study is to monitor participants for any delayed side effects that may possibly be related to the experimental gene-modified therapy product you received in the previous Kite-sponsored study. We also hope to learn more about the long-term effectiveness of the experimental gene-modified cell therapy product in treating your cancer.
- Principal Investigator: Jay Spiegel
- Study Phase: N/A
- Enrollment Status: Not Accepting